Overview
SLDB market data
Price History
SLDB price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.05 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.42 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $3.79 – $11.45 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $806.3 · P/B 2.44 · P/S 54.52.
Company News
Sophia Genetics, Ormat Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market SessionBenzinga · Jun 17, 2026, 12:10 PM
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics LandscapeGlobenewswire Inc · May 26, 2026, 5:15 PM
Wedbush Reiterates Outperform on Solid Biosciences, Maintains $16 Price TargetBenzinga · May 18, 2026, 12:40 PM
Wedbush Maintains Outperform on Solid Biosciences, Lowers Price Target to $16Benzinga · May 13, 2026, 2:45 PM
Piper Sandler Maintains Overweight on Solid Biosciences, Raises Price Target to $18Benzinga · May 13, 2026, 1:10 PM
Solid Biosciences Q1 EPS $(0.52) Misses $(0.44) EstimateBenzinga · May 12, 2026, 8:45 PM